Your browser doesn't support javascript.
loading
Preferences for Risks and Benefits of Islet Cell Transplantation for Persons With Type 1 Diabetes With History of Episodes of Severe Hypoglycemia: A Discrete-Choice Experiment to Inform Regulatory Decisions.
Wilson, Leslie; Kwok, Tiffany; Ma, Yanlei; Wong, Jenise; Ho, Martin; Ionova, Yelena; McGrath, Maureen; Mueller, Monica M; Gitelman, Stephen E; Irony, Telba.
Afiliação
  • Wilson L; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA.
  • Kwok T; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA.
  • Ma Y; Cornell University Department of Medicine, Ithaca, New York.
  • Wong J; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA.
  • Ho M; US Federal Drug Administration Center for Biologics Evaluation and Research (CBER), Silver Springs, MD.
  • Ionova Y; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA.
  • McGrath M; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA.
  • Mueller MM; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA.
  • Gitelman SE; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA.
  • Irony T; US Federal Drug Administration Center for Biologics Evaluation and Research (CBER), Silver Springs, MD.
Transplantation ; 106(8): e368-e379, 2022 08 01.
Article em En | MEDLINE | ID: mdl-35655355
ABSTRACT

BACKGROUND:

The advisory panel for US Food and Drug Administration (FDA) recently endorsed pancreatic islet cell transplantation (ICT) therapy for suboptimally controlled type 1 diabetes (T1D), and FDA approval is under consideration. An important part of regulatory approval includes the patient perspective, through discrete choice. We developed a discrete-choice instrument and used it to determine how 90 people with T1D weigh the risks and benefits of ICT to inform regulatory decisions.

METHODS:

Sawtooth software created a random, full-profile, balanced-overlap experimental design for a measure with 8 attributes of ICT risks/benefits, each with 3 to 5 levels. We asked 18 random task pairs, sociodemographics, diabetes management, and hypoglycemia questions. Analysis was performed using random parameters logistic regression technique.

RESULTS:

The strongest preference was for avoiding the highest chance (15%) of serious procedure-related complications (ß = -2.03, P < 0.001). The strongest positive preference was for gaining 5-y insulin independence (ß = 1.75, P < 0.001). The desire for 5-y HbA1C-defined clinical treatment success was also strong (ß = 1.39, P < 0.001). Subgroup analysis suggested strong gender differences with women showing much higher preferences for all benefits (68% higher for 5-y insulin independence), and men were generally more risk averse than women. Those with high versus low diabetes distress showed 3 times stronger preference for 5-y insulin independence but also twice preference to avoid risks of serious complications.

CONCLUSIONS:

Despite showing the most preference for avoiding serious ICT complications, people with T1D had a strong preference for achieving ICT benefits, especially insulin independence. We identified important attributes of ICT and demonstrated that patients are willing to make these trade-offs, showing support for the introduction of ICT.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante das Ilhotas Pancreáticas / Diabetes Mellitus Tipo 1 / Insulinas / Hipoglicemia Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante das Ilhotas Pancreáticas / Diabetes Mellitus Tipo 1 / Insulinas / Hipoglicemia Idioma: En Ano de publicação: 2022 Tipo de documento: Article